title: Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
abstract: OBJECTIVE
  To determine whether prevention of hyposalivation after curative radiotherapy (RT) to the head and neck improves patients' quality of life (QOL).
  
  
  METHODS
  Patients were to receive at least 50 Gy to 50% of the volume of the major salivary glands, provide unstimulated and stimulated saliva samples, and complete the University of Washington head-and-neck QOL tool before RT and 3 and 6 months after RT. Patients were randomized to receive pilocarpine 5 mg or placebo q.i.d.
  
  
  RESULTS
  A total of 249 patients was randomized between March 1998 and January 2000. Of these, 214 were eligible for QOL analysis. Patients were evenly distributed between arms by race, gender, tobacco use, tumor site, T stage (50% T2-T3), and salivary function. A Karnofsky performance status of 90% was more common in the pilocarpine arm. Twenty percent of the patients on the pilocarpine arm and 29% of the patients on the placebo arm were taking nutritional supplements. The placebo arm patients had greater mouth pain and chewing difficulties. Compliance for the QOL tool at 3 and 6 months was 65% and 50%, respectively. Despite statistically significant (p = 0.047 and p = 0.049, respectively) preservation of salivary function in the pilocarpine arm, patients on the pilocarpine arm reported difficulties with swallowing (75%), activity (80%), hyposalivation (64%), and taste (81%). No difference was noted between arms at 3 months in mucositis scores, with both arms demonstrating increased requirement for oral nutrients.
  
  
  CONCLUSIONS
  Objective prevention of hyposalivation did not affect patients' assessment of salivary function or QOL because of the greater impact mucositis plays in QOL after RT.
authors.affiliation: Edith McNaughton Ford Center for Radiation Oncology, Bon Secours Cottage Health Services, Grosse Pointe Farms, MI 48236, USA. jacquelyn_fisher@bshsi.com
authors.forename: Jacquelyn
authors.initials: J
authors.lastname: Fisher
authors.forename: Charles
authors.initials: C
authors.lastname: Scott
authors.forename: Charles W
authors.initials: CW
authors.lastname: Scarantino
authors.forename: Fran G
authors.initials: FG
authors.lastname: Leveque
authors.forename: Robert L
authors.initials: RL
authors.lastname: White
authors.forename: Marvin
authors.initials: M
authors.lastname: Rotman
authors.forename: D I
authors.initials: DI
authors.lastname: Hodson
authors.forename: Ruby F
authors.initials: RF
authors.lastname: Meredith
authors.forename: Robert
authors.initials: R
authors.lastname: Foote
authors.forename: David G
authors.initials: DG
authors.lastname: Bachman
authors.forename: Nancy
authors.initials: N
authors.lastname: Lee
mesh_terms: D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D010862:Pilocarpine / Q000627:therapeutic use*; D011594:Psychometrics; D011788:Quality of Life; D011879:Radiotherapy Dosage; D011795:Surveys and Questionnaires; D014987:Xerostomia / Q000209:etiology / Q000517:prevention & control*
chemical_list: D018721:Muscarinic Agonists; D010862:Pilocarpine